Stevens-Johnson Syndrome Caused by Enzalutamide: A Case Report and Literature Review
ObjectiveEnzalutamide is the most frequently prescribed compound for treating metastatic castration-resistant prostate cancer (mCRPC). Common adverse drug events of enzalutamide are febrile neutropenia, hot flashes, hypertension, and fatigue.MethodsWe present a case of a patient with mCRPC who recei...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2021-11-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2021.736975/full |
| _version_ | 1818406947005661184 |
|---|---|
| author | Min Deng Min Deng Huirong Chai Meng Yang Xueman Wei Wenjun Zhang Xuebin Wang Juanjuan Li Zhuo Wang Zhuo Wang Haitao Chen |
| author_facet | Min Deng Min Deng Huirong Chai Meng Yang Xueman Wei Wenjun Zhang Xuebin Wang Juanjuan Li Zhuo Wang Zhuo Wang Haitao Chen |
| author_sort | Min Deng |
| collection | DOAJ |
| description | ObjectiveEnzalutamide is the most frequently prescribed compound for treating metastatic castration-resistant prostate cancer (mCRPC). Common adverse drug events of enzalutamide are febrile neutropenia, hot flashes, hypertension, and fatigue.MethodsWe present a case of a patient with mCRPC who received enzalutamide and developed Stevens-Johnson syndrome (SJS). The culprit drug was confirmed using the Naranjo Adverse Drug Reaction Probability Scale. Clinical characteristics and management principles were analyzed in combination with literature reports.ResultsSJS occurred within two weeks of enzalutamide therapy. Supportive care such as steroid treatment led to a complete resolution of skin lesions and improved clinical symptoms after three weeks.ConclusionMost cutaneous adverse events occur early during enzalutamide therapy, and close observation should be given within two weeks of starting treatment. |
| first_indexed | 2024-12-14T09:20:02Z |
| format | Article |
| id | doaj.art-8f697cc520de4b24ac690fc280760438 |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-12-14T09:20:02Z |
| publishDate | 2021-11-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-8f697cc520de4b24ac690fc2807604382022-12-21T23:08:20ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2021-11-011110.3389/fonc.2021.736975736975Stevens-Johnson Syndrome Caused by Enzalutamide: A Case Report and Literature ReviewMin Deng0Min Deng1Huirong Chai2Meng Yang3Xueman Wei4Wenjun Zhang5Xuebin Wang6Juanjuan Li7Zhuo Wang8Zhuo Wang9Haitao Chen10College of life sciences and Biopharmaceuticals, Shenyang Pharmaceutical University, Shenyang, ChinaDepartment of Pharmacy, Shanghai Changhai Hospital, Naval Medical University, Shanghai, ChinaDepartment of Geriatrics, Shanghai Changhai Hospital, Naval Medical University, Shanghai, ChinaDepartment of Geriatrics, Shanghai Changhai Hospital, Naval Medical University, Shanghai, ChinaDepartment of Geriatrics, Shanghai Changhai Hospital, Naval Medical University, Shanghai, ChinaDepartment of Geriatrics, Shanghai Changhai Hospital, Naval Medical University, Shanghai, ChinaDepartment of Pharmacy, Shanghai Changhai Hospital, Naval Medical University, Shanghai, ChinaDepartment of Pharmacy, Shanghai Changhai Hospital, Naval Medical University, Shanghai, ChinaCollege of life sciences and Biopharmaceuticals, Shenyang Pharmaceutical University, Shenyang, ChinaDepartment of Pharmacy, Shanghai Changhai Hospital, Naval Medical University, Shanghai, ChinaDepartment of Geriatrics, Shanghai Changhai Hospital, Naval Medical University, Shanghai, ChinaObjectiveEnzalutamide is the most frequently prescribed compound for treating metastatic castration-resistant prostate cancer (mCRPC). Common adverse drug events of enzalutamide are febrile neutropenia, hot flashes, hypertension, and fatigue.MethodsWe present a case of a patient with mCRPC who received enzalutamide and developed Stevens-Johnson syndrome (SJS). The culprit drug was confirmed using the Naranjo Adverse Drug Reaction Probability Scale. Clinical characteristics and management principles were analyzed in combination with literature reports.ResultsSJS occurred within two weeks of enzalutamide therapy. Supportive care such as steroid treatment led to a complete resolution of skin lesions and improved clinical symptoms after three weeks.ConclusionMost cutaneous adverse events occur early during enzalutamide therapy, and close observation should be given within two weeks of starting treatment.https://www.frontiersin.org/articles/10.3389/fonc.2021.736975/fullenzalutamideStevens-Johnson syndromedrug eruptioncutaneous adverse eventsprostate cancer |
| spellingShingle | Min Deng Min Deng Huirong Chai Meng Yang Xueman Wei Wenjun Zhang Xuebin Wang Juanjuan Li Zhuo Wang Zhuo Wang Haitao Chen Stevens-Johnson Syndrome Caused by Enzalutamide: A Case Report and Literature Review Frontiers in Oncology enzalutamide Stevens-Johnson syndrome drug eruption cutaneous adverse events prostate cancer |
| title | Stevens-Johnson Syndrome Caused by Enzalutamide: A Case Report and Literature Review |
| title_full | Stevens-Johnson Syndrome Caused by Enzalutamide: A Case Report and Literature Review |
| title_fullStr | Stevens-Johnson Syndrome Caused by Enzalutamide: A Case Report and Literature Review |
| title_full_unstemmed | Stevens-Johnson Syndrome Caused by Enzalutamide: A Case Report and Literature Review |
| title_short | Stevens-Johnson Syndrome Caused by Enzalutamide: A Case Report and Literature Review |
| title_sort | stevens johnson syndrome caused by enzalutamide a case report and literature review |
| topic | enzalutamide Stevens-Johnson syndrome drug eruption cutaneous adverse events prostate cancer |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2021.736975/full |
| work_keys_str_mv | AT mindeng stevensjohnsonsyndromecausedbyenzalutamideacasereportandliteraturereview AT mindeng stevensjohnsonsyndromecausedbyenzalutamideacasereportandliteraturereview AT huirongchai stevensjohnsonsyndromecausedbyenzalutamideacasereportandliteraturereview AT mengyang stevensjohnsonsyndromecausedbyenzalutamideacasereportandliteraturereview AT xuemanwei stevensjohnsonsyndromecausedbyenzalutamideacasereportandliteraturereview AT wenjunzhang stevensjohnsonsyndromecausedbyenzalutamideacasereportandliteraturereview AT xuebinwang stevensjohnsonsyndromecausedbyenzalutamideacasereportandliteraturereview AT juanjuanli stevensjohnsonsyndromecausedbyenzalutamideacasereportandliteraturereview AT zhuowang stevensjohnsonsyndromecausedbyenzalutamideacasereportandliteraturereview AT zhuowang stevensjohnsonsyndromecausedbyenzalutamideacasereportandliteraturereview AT haitaochen stevensjohnsonsyndromecausedbyenzalutamideacasereportandliteraturereview |